Thomas Bachelot
Impact in
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 172
- HER2/EGFR in Cancer Research 69
- Cancer Treatment and Pharmacology 47
- Lung Cancer Research Studies 18
-
- Breast Cancer Treatment Studies 43
- Cancer Genomics and Diagnostics 19
- Co-authors
- Jean‐Yves Blay (33 shared papers)Isabelle L. Ray-Coquard (39 shared papers)Isabelle Treilleux (35 shared papers)Mario Campone (45 shared papers)Christine Ménétrier‐Caux (14 shared papers)Jean-Marc Ferrero (20 shared papers)Claire Cropet (10 shared papers)Jean‐Yves Pierga (23 shared papers)
- Journals
- Annals of Oncology (61 papers)European Journal of Cancer (35 papers)The Lancet Oncology (16 papers)Breast Cancer Research and Treatment (15 papers)Journal of Clinical Oncology (14 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Thomas Bachelot
339 papers receiving 23.6k citations
Thomas Bachelot's Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 11.8k
- Cancer Research 5.0k
- Pulmonary and Respiratory Medicine 8.5k
- Genetics 1.7k
- Immunology 2.2k
Countries citing papers authored by Thomas Bachelot
This map shows the geographic impact of Thomas Bachelot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Bachelot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Bachelot more than expected).
Fields of papers citing papers by Thomas Bachelot
This network shows the impact of papers produced by Thomas Bachelot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Bachelot. The network helps show where Thomas Bachelot may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Bachelot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 359 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2011 | 2395 |
| 2 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Hit paper breakdown → | 2016 | 1544 |
| 3 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 971 |
| 4 | Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas Hit paper breakdown → | 2009 | 659 |
| 5 | 2009 | 612 | |
| 6 | Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Hit paper breakdown → | 2012 | 610 |
| 7 | Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study Hit paper breakdown → | 2012 | 591 |
| 8 | Genomic characterization of metastatic breast cancers Hit paper breakdown → | 2019 | 529 |
| 9 | Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 521 |
| 10 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial Hit paper breakdown → | 2020 | 428 |
| 11 | EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours Hit paper breakdown → | 2021 | 405 |
| 12 | 2019 | 387 | |
| 13 | 2004 | 376 | |
| 14 | 2017 | 336 | |
| 15 | 2014 | 320 | |
| 16 | Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Hit paper breakdown → | 2016 | 314 |
| 17 | 2004 | 302 | |
| 18 | Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial Hit paper breakdown → | 2023 | 294 |
| 19 | 2012 | 288 | |
| 20 | Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study Hit paper breakdown → | 2021 | 279 |
About Thomas Bachelot
Thomas Bachelot is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Genetics, having authored 359 papers that have together received 24.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (73 papers), HER2/EGFR in Cancer Research (69 papers), Cancer Treatment and Pharmacology (47 papers), Breast Cancer Treatment Studies (43 papers), PI3K/AKT/mTOR signaling in cancer (26 papers), Brain Metastases and Treatment (26 papers), Cancer Genomics and Diagnostics (19 papers) and Lung Cancer Research Studies (18 papers). The work is most often cited by research in Oncology (11.8k citations), Cancer Research (5.0k citations), Pulmonary and Respiratory Medicine (8.5k citations), Genetics (1.7k citations) and Immunology (2.2k citations). Thomas Bachelot has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Jean‐Yves Blay, Isabelle L. Ray-Coquard, Isabelle Treilleux, Mario Campone, Christine Ménétrier‐Caux, Jean-Marc Ferrero, Claire Cropet, Jean‐Yves Pierga, Veronique C Dieras and Fabrice André. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, The Lancet Oncology, Breast Cancer Research and Treatment and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.